HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Aoki, F. Articles by Mae, T. Search for Related Content PubMed PubMed Citation Articles by Aoki, F. Articles by Mae, T.

Clinical Safety of Licorice Flavonoid Oil (LFO) and Pharmacokinetics of Glabridin in Healthy Humans

Functional Food Ingredients Division, (F.A., S.Y., Y.T., N.A.)
Life Science Research Laboratories (M.K.), Life Science RD Center, Kaneka Corporation, Hyogo
Functional Food Ingredients Division, Kaneka Corporation, Osaka (K.N., T.M.)
Haradoi Hospital (H.I.)
Tenjin Sogo Clinic (K.N.), Fukuoka, JAPAN

View larger version (23K): [in this window] [in a new window]   Fig. 1. Plasma glabridin (ng/mL) in healthy male subjects (n = 5) after a single oral administration of 300, 600 or 1200 mg licorice flavonoid oil (LFO). Symbols are expressed as mean ± SEM.

View larger version (20K): [in this window] [in a new window]   Fig. 2. Relationship between dose of LFO and Cmax (upper panel) or AUC0–24h (lower panel) in healthy male subjects after a single administration of 300, 600 or 1200 mg licorice flavonoid oil (LFO). In each figure, linear regression lines and correlation coefficients (r) are described. AUC = area under the curve, Cmax = the maximum concentration in plasma.

View larger version (34K): [in this window] [in a new window]   Fig. 3. Simulation of plasma glabridin concentrations after once daily oral administration of 300, 600 or 1200 mg licorice flavonoid oil (LFO) for 7 days. The simulation was based on the one-compartmental model analysis of plasma glabridin in the single-dose study of 300, 600 and 1200 mg LFO.